Published in Infect Immun on September 01, 1995
Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with mycobacterium tuberculosis. J Exp Med (1997) 5.48
Transient loss of resistance to pulmonary tuberculosis in p47(phox-/-) mice. Infect Immun (2000) 1.87
Interleukin-6 induces early gamma interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis infection. Infect Immun (2000) 1.83
The course of Mycobacterium tuberculosis infection in the lungs of mice lacking expression of either perforin- or granzyme-mediated cytolytic mechanisms. Infect Immun (1997) 1.73
Interleukin-12 in infectious diseases. Clin Microbiol Rev (1997) 1.63
CTLA-4 blockade enhances the immune response induced by mycobacterial infection but does not lead to increased protection. Infect Immun (1999) 1.23
A Toll-like receptor-2-directed fusion protein vaccine against tuberculosis. Clin Vaccine Immunol (2007) 1.14
Th1 cytokines facilitate CD8-T-cell-mediated early resistance to infection with Mycobacterium tuberculosis in old mice. Infect Immun (2006) 1.09
Old mice express a transient early resistance to pulmonary tuberculosis that is mediated by CD8 T cells. Infect Immun (2002) 1.01
Evidence for a reduced chemokine response in the lungs of beige mice infected with Mycobacterium avium. Immunology (1997) 0.99
CD8 T Cells in old mice contribute to the innate immune response to Mycobacterium tuberculosis via interleukin-12p70-dependent and antigen-independent production of gamma interferon. Infect Immun (2009) 0.95
Attenuated response of aged mice to respiratory Francisella novicida is characterized by reduced cell death and absence of subsequent hypercytokinemia. PLoS One (2010) 0.93
A model on the influence of age on immunity to infection with Mycobacterium tuberculosis. Exp Gerontol (2007) 0.86
Interleukin-12 is sufficient to promote antigen-independent interferon-gamma production by CD8 T cells in old mice. Immunology (2009) 0.86
Genetically diverse mice are novel and valuable models of age-associated susceptibility to Mycobacterium tuberculosis. Immun Ageing (2014) 0.77
Attrition of T-cell functions and simultaneous upregulation of inhibitory markers correspond with the waning of BCG-induced protection against tuberculosis in mice. PLoS One (2014) 0.76
CD95 expression in aged mice infected with tuberculosis. Infect Immun (1998) 0.75
Influence of advanced age on Mycobacterium bovis BCG vaccination in guinea pigs aerogenically infected with Mycobacterium tuberculosis. Clin Vaccine Immunol (2010) 0.75
Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell (1987) 9.41
Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med (1991) 7.52
Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc Natl Acad Sci U S A (1993) 6.87
Cloning and expression of murine IL-12. J Immunol (1992) 4.92
Analysis of cytokine mRNA expression during primary granuloma formation induced by eggs of Schistosoma mansoni. J Immunol (1993) 3.34
Endogenous interleukin 12 (IL-12) regulates granuloma formation induced by eggs of Schistosoma mansoni and exogenous IL-12 both inhibits and prophylactically immunizes against egg pathology. J Exp Med (1994) 2.99
Isolation and chromosomal localization of cDNAs encoding a novel human lymphocyte cell surface molecule, LAM-1. Homology with the mouse lymphocyte homing receptor and other human adhesion proteins. J Exp Med (1989) 2.67
The rising age of the tuberculosis patient: a sign of success and failure. J Infect Dis (1980) 1.48
Aging and immunity to tuberculosis: increased susceptibility of old mice reflects a decreased capacity to generate mediator T lymphocytes. J Immunol (1987) 1.32
Tuberculosis in the geriatric patient. J Am Geriatr Soc (1983) 1.20
Evidence for a defective accumulation of protective T cells in old mice infected with Mycobacterium tuberculosis. Cell Immunol (1993) 1.11
Host defense mechanisms and aging. Semin Oncol (1989) 1.09
Hematogenous dissemination of Mycobacterium tuberculosis in patients with AIDS. Rev Infect Dis (1992) 0.99
Effect of aging on antimicrobial immunity: old mice display a normal capacity for generating protective T cells and immunologic memory in response to infection with Listeria monocytogenes. J Immunol (1985) 0.96
Retracted Minimal effect of advanced aging on susceptibility of mice to infection with Mycobacterium tuberculosis. J Infect Dis (1993) 0.85
Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med (1993) 17.01
A survey of products licensed in the United Kingdom from 1971-1981. Br J Clin Pharmacol (1981) 11.40
The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with Mycobacterium tuberculosis. J Immunol (1987) 6.12
Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with mycobacterium tuberculosis. J Exp Med (1997) 5.48
Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med (1996) 5.38
Therapeutic-class wars--drug promotion in a competitive marketplace. N Engl J Med (1994) 4.35
Adoptive protection of the Mycobacterium tuberculosis-infected lung. Dissociation between cells that passively transfer protective immunity and those that transfer delayed-type hypersensitivity to tuberculin. Cell Immunol (1984) 4.00
Protection against Mycobacterium tuberculosis infection by adoptive immunotherapy. Requirement for T cell-deficient recipients. J Exp Med (1983) 3.79
Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis. Tuber Lung Dis (1997) 3.55
Cytokine secretion by CD4 T lymphocytes acquired in response to Mycobacterium tuberculosis infection. J Immunol (1993) 3.51
The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology (1995) 3.45
Ethics committees for clinical research. Experience in the United Kingdom. Drugs (1989) 3.23
Protection from respiratory virus infections can be mediated by antigen-specific CD4(+) T cells that persist in the lungs. J Exp Med (2001) 3.19
Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect Immun (1998) 3.14
Bubonic plague in biblical times. J R Soc Med (2000) 2.86
New procedures affecting the conduct of clinical trials in the United Kingdom. Br Med J (Clin Res Ed) (1981) 2.79
Demography of the UK adverse reactions register of spontaneous reports. Health Trends (1984) 2.73
Neutrophils play a protective nonphagocytic role in systemic Mycobacterium tuberculosis infection of mice. Infect Immun (2000) 2.63
Role of gamma interferon and tumor necrosis factor alpha during T-cell-independent and -dependent phases of Mycobacterium avium infection. Infect Immun (1994) 2.52
An anti-inflammatory role for gamma delta T lymphocytes in acquired immunity to Mycobacterium tuberculosis. J Immunol (1997) 2.46
Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob Agents Chemother (1996) 2.43
Structural basis of capacity of lipoarabinomannan to induce secretion of tumor necrosis factor. Infect Immun (1992) 2.33
The protective immune response to Mycobacterium tuberculosis. Curr Opin Immunol (1995) 2.21
A survey of the first year of operation of the new procedure affecting the conduct of clinical trials in the United Kingdom. Br J Clin Pharmacol (1983) 2.19
Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis. Immunology (1995) 2.19
Adverse reactions to nitrofurantoin in the United Kingdom, Sweden, and Holland. Br Med J (Clin Res Ed) (1982) 2.12
Drug-resistant strains of Mycobacterium tuberculosis exhibit a range of virulence for mice. Infect Immun (1995) 2.08
Chemokine response in mice infected with Mycobacterium tuberculosis. Infect Immun (1995) 1.99
Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect Immun (1999) 1.95
Voluntary systems of adverse reaction reporting--Part I. Adverse Drug React Acute Poisoning Rev (1985) 1.95
Expression of the nitric oxide synthase 2 gene is not essential for early control of Mycobacterium tuberculosis in the murine lung. Infect Immun (2000) 1.92
Transient loss of resistance to pulmonary tuberculosis in p47(phox-/-) mice. Infect Immun (2000) 1.87
Cu,Zn superoxide dismutase of Mycobacterium tuberculosis contributes to survival in activated macrophages that are generating an oxidative burst. Infect Immun (2001) 1.84
Interleukin-6 induces early gamma interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis infection. Infect Immun (2000) 1.83
Demonstration of acquired resistance in Bcgr inbred mouse strains infected with a low dose of BCG montreal. Clin Exp Immunol (1984) 1.82
Characterization of murine lung dendritic cells infected with Mycobacterium tuberculosis. Infect Immun (2001) 1.80
Temporal and spatial arrangement of lymphocytes within lung granulomas induced by aerosol infection with Mycobacterium tuberculosis. Infect Immun (2001) 1.77
T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. J Immunol (2000) 1.76
Expression of memory immunity in the lung following re-exposure to Mycobacterium tuberculosis. Tuber Lung Dis (1997) 1.76
Survey of the spontaneous adverse drug reaction reporting schemes in fifteen countries. Br J Clin Pharmacol (1986) 1.74
The course of Mycobacterium tuberculosis infection in the lungs of mice lacking expression of either perforin- or granzyme-mediated cytolytic mechanisms. Infect Immun (1997) 1.73
Resistance of various strains of mycobacteria to killing by activated macrophages in vivo. J Immunol (1983) 1.72
Susceptibility of a panel of virulent strains of Mycobacterium tuberculosis to reactive nitrogen intermediates. Infect Immun (1997) 1.70
Genetic control of natural resistance to nontuberculous mycobacterial infections in mice. Infect Immun (1986) 1.68
Effector mechanisms involved in cytokine-mediated bacteriostasis of Mycobacterium avium infections in murine macrophages. Immunology (1993) 1.67
Voluntary systems of adverse reaction reporting--Part II. Adverse Drug React Acute Poisoning Rev (1986) 1.62
Boosting vaccine for tuberculosis. Infect Immun (2001) 1.61
Long-term hormone implant therapy--hormonal and clinical effects. Obstet Gynecol (1986) 1.58
Profound deletion of mature T cells in vivo by chronic exposure to exogenous superantigen. J Immunol (1993) 1.58
Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis. Antimicrob Agents Chemother (1996) 1.57
Maternal drug histories and central nervous system anomalies. Arch Dis Child (1984) 1.56
Six months experience of new procedures affecting the conduct of clinical trials in the United Kingdom. Br J Clin Pharmacol (1982) 1.53
Role of mononuclear phagocytes in expression of resistance and susceptibility to Mycobacterium avium infections in mice. Infect Immun (1986) 1.49
Listeria monocytogenes infection in beta 2 microglobulin-deficient mice. Infect Immun (1993) 1.48
Metronidazole therapy in mice infected with tuberculosis. Antimicrob Agents Chemother (1999) 1.45
Immunological basis for reactivation of tuberculosis in mice. Infect Immun (2001) 1.42
Induction of a type 1 immune response to a recombinant antigen from Mycobacterium tuberculosis expressed in Mycobacterium vaccae. Infect Immun (1997) 1.41
CD8- and CD95/95L-dependent mechanisms of resistance in mice with chronic pulmonary tuberculosis. Am J Respir Cell Mol Biol (2001) 1.40
Original pack dispensing. Br Med J (Clin Res Ed) (1987) 1.40
Evolution of CD4 T-cell subsets following infection of naive and memory immune mice with Mycobacterium tuberculosis. Infect Immun (1994) 1.40
The yellow card: mark II. BMJ (1991) 1.39
Who will fund postgraduate education after 1992? J R Coll Physicians Lond (1991) 1.38
Effect of rifabutin on disseminated Mycobacterium avium infections in thymectomized, CD4 T-cell-deficient mice. Antimicrob Agents Chemother (1990) 1.38
Efficacy of Mycobacterium bovis BCG vaccination in mice undergoing prior pulmonary infection with atypical mycobacteria. Infect Immun (1984) 1.36
Capacity of Mycobacterium avium isolates to grow well or poorly in murine macrophages resides in their ability to induce secretion of tumor necrosis factor. Infect Immun (1992) 1.36
Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect Immun (2000) 1.36
Crossprotection against nontuberculous mycobacterial infections by Mycobacterium tuberculosis memory immune T lymphocytes. J Exp Med (1986) 1.36
A novel nonclassic beta2-microglobulin-restricted mechanism influencing early lymphocyte accumulation and subsequent resistance to tuberculosis in the lung. Am J Respir Cell Mol Biol (2000) 1.35
Granuloma formation is required to contain bacillus growth and delay mortality in mice chronically infected with Mycobacterium tuberculosis. Immunology (1999) 1.35
Prevention of exercise-induced asthma by indoramin. Br Med J (1974) 1.33
Aging and immunity to tuberculosis: increased susceptibility of old mice reflects a decreased capacity to generate mediator T lymphocytes. J Immunol (1987) 1.32
Immune response to atypical mycobacteria: immunocompetence of heavily infected mice measured in vivo fails to substantiate immunosuppression data obtained in vitro. Infect Immun (1984) 1.31
Inflammation and lymphocyte activation during mycobacterial infection in the interferon-gamma-deficient mouse. Cell Immunol (2001) 1.31
The intravenous model of murine tuberculosis is less pathogenic than the aerogenic model owing to a more rapid induction of systemic immunity. Scand J Immunol (1999) 1.30
Dissemination of enteric Mycobacterium avium infections in mice rendered immunodeficient by thymectomy and CD4 depletion or by prior infection with murine AIDS retroviruses. Infect Immun (1992) 1.29
Hippocampal lesions disrupt navigation based on cognitive maps but not heading vectors. Nature (1998) 1.29
Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model. Antimicrob Agents Chemother (1998) 1.29
Immunogenicity and protective efficacy of DNA vaccines encoding secreted and non-secreted forms of Mycobacterium tuberculosis Ag85A. Tuber Lung Dis (1999) 1.27
Mycobacterium tuberculosis aerogenic rechallenge infections in B cell-deficient mice. Tuber Lung Dis (1997) 1.24
Rapid screening for cold agglutinins in pneumonia. Ann Intern Med (1969) 1.23
Hypertension, diabetes mellitus, and blood groups in benign prostatic hypertrophy. Br J Urol (1966) 1.22
Adequate expression of protective immunity in the absence of granuloma formation in Mycobacterium tuberculosis-infected mice with a disruption in the intracellular adhesion molecule 1 gene. Infect Immun (1998) 1.22
Preliminary studies of a new bronchodilator (WG 253) in man. J Clin Pharmacol New Drugs (1971) 1.20
Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int (2006) 1.19
A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions. Antimicrob Agents Chemother (1994) 1.19
Metabolism of pyruvate and glucose by intact cells of Helicobacter pylori studied by 13C NMR spectroscopy. Microbiology (1994) 1.18